FreshPatents.com Logo


new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)


Similar
Filing Names

Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals Inc_20100128
Regeneron Pharmaceuticals Inc_20131212

Popular
Companies


Web
Adobe patents
Akamai patents
Amazon patents
Apple patents
Ebay patents
Facebook patents
Google patents
IBM patents
Linkedin patents
Microsoft patents
Oracle patents
Red Hat patents
Yahoo patents

Food/Health
Adidas
Nike patents
Pfizer patents
Monsanto patents
Medtronic patents
Kraft patents

Transportation
Boeing patents
Tesla Motors patents

Telecom
Qualcomm patents
Motorola patents
Nokia patents
RIMM patents

Industrial/Electronics
AMD
Applied Materials
Seagate patents
General Electric
Caterpillar patents
Samsung
Wal-mart patents

Ticker Symbols

Regeneron Pharmaceuticals, Inc. patents


      
Recent patent applications related to Regeneron Pharmaceuticals, Inc.. Regeneron Pharmaceuticals, Inc. is listed as an Agent/Assignee. Note: Regeneron Pharmaceuticals, Inc. may have other listings under different names/spellings. We're not affiliated with Regeneron Pharmaceuticals, Inc., we're just tracking patents.

ARCHIVE: New 2014 2013 2012 2011 2010 2009 | Company Directory "R" | Regeneron Pharmaceuticals, Inc.-related inventors



Search recent Press Releases: Regeneron Pharmaceuticals, Inc.-related press releases
Count Application # Date Regeneron Pharmaceuticals, Inc. patents (updated weekly) - BOOKMARK this page
12014028987609/25/14Mice that make heavy chain antibodies
22014027164209/18/14Il-33 antagonists and uses thereof
32014027165309/18/14Human antibodies to respiratory syncytial virus f protein and methods of use thereof
42014027165809/18/14Anti-il-33 antibodies and uses thereof
52014027168109/18/14High affinity human antibodies to human il-4 receptor
62014027309509/18/14Serum-free cell culture medium
72014027548909/18/14Apelin fusion proteins and uses thereof
82014028315809/18/14Rodents with conditional acvr1 mutant alleles
92014025539009/11/14Method of treating rheumatoid arthritis with an anti-il-6r antibody
102014025541909/11/14Method of treating stress hyperglycemia with human antibodies to the glucagon receptor
112014025542909/11/14Methods of treating autoimmune diseases with dll4 antagonists
122014025599509/11/14High affinity antibodies to human il-6 receptor
132014024866409/04/14Readily isolated bispecific antibodies with native immunoglobulin format
142014024350408/28/14Antibodies comprising chimeric constant domains
152014024546608/28/14Humanized t cell co-receptor mice
162014024546708/28/14Genetically modified major histocompatibility complex mice
172014024546808/28/14Non-human animals with modified immunoglobulin heavy chain sequences
182014022002308/07/14Method of treating osteoarthritis with an antibody to ngf
192014021377307/31/14Adam6 mice
202014019655007/17/14Systems and devices for sample handling
212014019976107/17/14Promoter-regulated differentiation-dependent self-deleting cassette
222014019340207/10/14Anti-pdgfr-beta antibodies and uses thereof
232014019459707/10/14Modified chimeric polypeptides with improved pharmacokinetic properties
242014018990007/03/14Mirna-regulated differentiation-dependent self-deleting cassette
252014017887906/26/14Compositions and methods for modifying cells
262014017990306/26/14High affinity human antibodies to human protease-activated receptor 2
272014015470106/05/14Humanized fc gamma r mice
282014015568906/05/14Methods of modifying genes in eukaryotic cells
292014015744506/05/14Low affinity fcgr deficient mice
302014013797805/22/14System and methods for use in dispensing biopharmaceutical materials
312014013797805/22/14System and methods for use in dispensing biopharmaceutical materials
322014013416905/15/14Methods of treating ovarian cancer with dll4 antagonists
332014013418905/15/14Anti-prokineticin receptor (prokr) antibodies and uses thereof
342014013471905/15/14Recombinant cell surface capture proteins
352014013727505/15/14Hybrid light chain mice
362014013416905/15/14Methods of treating ovarian cancer with dll4 antagonists
372014013418905/15/14Anti-prokineticin receptor (prokr) antibodies and uses thereof
382014013471905/15/14Recombinant cell surface capture proteins
392014013727505/15/14Hybrid light chain mice
402014013019305/08/14Mice that make vl binding proteins
412014013019405/08/14Mice that make vl binding proteins
422014013019305/08/14Mice that make vl binding proteins
432014013019405/08/14Mice that make vl binding proteins
442014012010905/01/14Human antibodies to human tnf-like ligand 1a (tl1a)
452014012010905/01/14Human antibodies to human tnf-like ligand 1a (tl1a)
462014011293004/24/14Methods for treating or preventing malaria by administering an antibody that specifically binds angiopoietin-2 (ang-2)
472014011293004/24/14Methods for treating or preventing malaria by administering an antibody that specifically binds angiopoietin-2 (ang-2)
482014009931204/10/14Methods for treating hypercholesterolemia and reducing ldl-c using antibodies to pcsk9
492014009931204/10/14Methods for treating hypercholesterolemia and reducing ldl-c using antibodies to pcsk9
502014009931204/10/14Methods for treating hypercholesterolemia and reducing ldl-c using antibodies to pcsk9
512014008829503/27/14Anti-cd3 antibodies, bispecific antigen-binding molecules that bind cd3 and cd20, and uses thereof
522014008829503/27/14Anti-cd3 antibodies, bispecific antigen-binding molecules that bind cd3 and cd20, and uses thereof
532014008276003/20/14Non-human animals expressing ph-sensitive immunoglobulin sequences
542014008276003/20/14Non-human animals expressing ph-sensitive immunoglobulin sequences
552014007256303/13/14Methods and compositions comprising a combination of an anti-erbb3 antibody and an anti-egfr antibody
562014007258303/13/14Methods for treating atopic dermatitis by administering an il-4r antagonist
572014007297903/13/14Isolating cells expressing secreted proteins
582014007298003/13/14Isolating cells expressing secreted proteins
592014007301003/13/14Methods of modifying eukaryotic cells
602014007558603/13/14Parental cell lines for making cassette-free f1 progeny
612014007256303/13/14Methods and compositions comprising a combination of an anti-erbb3 antibody and an anti-egfr antibody
622014007258303/13/14Methods for treating atopic dermatitis by administering an il-4r antagonist
632014007297903/13/14Isolating cells expressing secreted proteins
642014007298003/13/14Isolating cells expressing secreted proteins
652014007301003/13/14Methods of modifying eukaryotic cells
662014007558603/13/14Parental cell lines for making cassette-free f1 progeny
672014005690302/27/14Human antibodies to gfr alpha 3 and methods of use thereof
682014005690702/27/14Anti-asic1 antibodies and uses thereof
692014004473002/13/14Anti-pcsk9 antibodies with ph-dependent binding characteristics
702014004106802/06/14Methods of modifying eukaryotic cells
712014003333601/30/14Methods of modifying eukaryotic cells
722014003333701/30/14Methods of modifying eukaryotic cells
732014002363701/23/14Methods of modifying eukaryotic cells
742014001722801/16/14Humanized light chain mice
752014001722901/16/14Methods of modifying eukaryotic cells
762014001723801/16/14Methods of modifying eukaryotic cells
772014001769501/16/14Isolating cells expressing secreted proteins
782014001778101/16/14Methods of modifying eukaryotic cells
792014001778201/16/14Methods for modifying eukaryotic cells
802014001852201/16/14Methods of modifying eukaryotic cells
812014002012401/16/14Methods of modifying eukaryotic cells
822014002012501/16/14Methods of modifying eukaryotic cells
832014001345601/09/14Histidine engineered light chain antibodies and genetically modified non-human animals for generating the same
842014001345701/09/14Methods of modifying eukaryotic cells
852013034453812/26/13Human antibodies to the glucagon receptor
862013034010412/19/13Humanized il-7 rodents
872013033305712/12/13Humanized non-human animals with restricted immunoglobulin heavy chain loci
882013033305712/12/13Humanized non-human animals with restricted immunoglobulin heavy chain loci
892013032326012/05/13Stabilized formulations containing anti-dll4 antibodies
902013032326112/05/13Purified antibody composition
912013032378812/05/13Production cell line enhancers
922013032379012/05/13Human lambda light chain mice
932013032379112/05/13Restricted immunoglobulin heavy chain mice
942013032664712/05/13Human lambda light chain mice
952013030967011/21/13Nuclease-mediated targeting with large targeting vectors
962013031212811/21/13Promoter-regulated differentiation-dependent self-deleting cassette
972013031212911/21/13Promoter-regulated differentiation-dependent self-deleting cassette
982013029509711/07/13Human antibodies to fel d1 and methods of use thereof
992013028075810/24/13Fusion polypeptides capable of activating receptors
1002013027307010/17/13Methods for treating or preventing influenza virus infection by administering a serine protease inhibitor
1012013026657410/10/13Human antibodies to human angiopoietin-like protein 4
1022013025987610/03/13Anti-hla-b*27 antibodies and uses thereof
1032013025988110/03/13Fusion polypeptides capable of activating receptors
1042013026105610/03/13Vegf antagonist formulations
1052013025172809/26/13Method of treating stress hyperglycemia with human antibodies to the glucagon receptor
1062013025491109/26/13Adam6 mice
1072013024377509/19/13Multispecific antigen-binding molecules and uses thereof
1082013024378409/19/13Methods for reducing lipoprotein(a) levels by administering an inhibitor of proprotein convertase subtilisin kexin-9 (pcsk9)
1092013024723409/19/13Histidine engineered light chain antibodies and genetically modified non-human animals for generating the same
1102013024723509/19/13Mice that produce antigen-binding proteins with ph-dependent binding characteristics
1112013024723609/19/13Non-human animals expressing ph-sensitive immunoglobulin sequences
1122013023053109/05/13Human antibodies to clostridium difficile toxins
1132013023053309/05/13Methods of treating systemic lupus erythematosus (sle) using anti-cd48 antibodies
1142013021654708/22/13Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof
1152013021654708/22/13Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof
1162013020949208/15/13Anti-tie2 antibodies and uses thereof
1172013021013708/15/13Methods of modifying eukaryotic cells
1182013021271908/15/13Humanized rodents that express heavy chain containing vl domains
1192013020949208/15/13Anti-tie2 antibodies and uses thereof
1202013021013708/15/13Methods of modifying eukaryotic cells
1212013021271908/15/13Humanized rodents that express heavy chain containing vl domains
1222013019587808/01/13Anti-asic1 antibodies and uses thereof
1232013019887908/01/13Humanized universal light chain mice
1242013019888008/01/13Mice expressing a limited immunoglobulin light chain repertoire
1252013019587808/01/13Anti-asic1 antibodies and uses thereof
1262013019887908/01/13Humanized universal light chain mice
1272013019888008/01/13Mice expressing a limited immunoglobulin light chain repertoire
1282013018679707/25/13Stabilized formulations containing anti-ang2 antibodies
1292013018927707/25/13Stabilized formulations containing anti-pcsk9 antibodies
1302013018679707/25/13Stabilized formulations containing anti-ang2 antibodies
1312013018927707/25/13Stabilized formulations containing anti-pcsk9 antibodies
1322013018420507/18/13Antitumor combinations containing a vegf-inhibiting agent and 5fu or a derivative thereof
1332013018581907/18/13Genetically modified major histocompatibility complex animals
1342013018582007/18/13Genetically modified major histocompatibility complex animals
1352013018582107/18/13Common light chain mouse
1362013018420507/18/13Antitumor combinations containing a vegf-inhibiting agent and 5fu or a derivative thereof
1372013018581907/18/13Genetically modified major histocompatibility complex animals
1382013018582007/18/13Genetically modified major histocompatibility complex animals
1392013018582107/18/13Common light chain mouse
1402013017114907/04/13Anti-angptl3 antibodies and uses thereof
1412013017114907/04/13Anti-angptl3 antibodies and uses thereof
1422013016478606/27/13Fucosylation-deficient cells
1432013016478606/27/13Fucosylation-deficient cells
1442013015731306/20/13High affinity antibodies to human il-6 receptor
1452013016015306/20/13Humanized light chain mice
1462013015731306/20/13High affinity antibodies to human il-6 receptor
1472013016015306/20/13Humanized light chain mice
1482013014974406/13/13Methods for producing a fusion protein capable of binding vegf
1492013014974406/13/13Methods for producing a fusion protein capable of binding vegf
1502013013710105/30/13Methods of modifying eukaryotic cells
1512013013710105/30/13Methods of modifying eukaryotic cells
1522013012972205/23/13Methods for treating cancer by administering an anti-ang-2 antibody
1532013012983005/23/13Polymer protein microparticles
1542013013037205/23/13Enhanced expression and stability regions
1552013013038805/23/13Methods of modifying eurakyotic cells
1562013012972205/23/13Methods for treating cancer by administering an anti-ang-2 antibody
1572013012983005/23/13Polymer protein microparticles
1582013013037205/23/13Enhanced expression and stability regions
1592013013038805/23/13Methods of modifying eurakyotic cells
1602013012200305/16/13Methods of inhibiting tumor growth by antagonizing il-6 receptor
1612013012200705/16/13Compositions and methods for increasing muscle mass and muscle strength by specifically antagonizing gdf8 and or activin a
1622013012200305/16/13Methods of inhibiting tumor growth by antagonizing il-6 receptor
1632013012200705/16/13Compositions and methods for increasing muscle mass and muscle strength by specifically antagonizing gdf8 and or activin a
1642013011787305/09/13Humanized il-6 and il-6 receptor
1652013011787305/09/13Humanized il-6 and il-6 receptor
1662013010905305/02/13Genetically modified t cell receptor mice
1672013011161605/02/13Genetically modified major histocompatibility complex mice
1682013011161705/02/13Genetically modified major histocompatibility complex mice
1692013009556504/18/13Mirna-regulated differentiation-dependent self-deleting cassette
1702013009628704/18/13Restricted immunoglobulin heavy chain mice
1712013008429704/04/13Anti-erbb3 antibodies and uses thereof
1722013008463504/04/13Cell culture compositions capable of producing a vegf-binding fusion polypeptide
1732013008526604/04/13Anti-pcsk9 antibodies with ph-dependent binding characteristics
1742013007867503/28/13High affinity human antibodies to human il-4 receptor
1752013006483403/14/13Methods for treating hypercholesterolemia using antibodies to pcsk9
1762013004549202/21/13Methods for making fully human bispecific antibodies using a common light chain
1772013003490202/07/13Fusion polypeptides capable of activating receptors
1782013002889201/31/13Method of treating osteoarthritis with an antibody to ngf
1792012032210812/20/12Adam6 mice
1802012032349712/20/12Non-hypergeometric overlap probability
1812012025809810/11/12Method of treating rheumatoid arthritis with an anti-il-6r antibody
1822012026035710/11/12Low affinity fcgr deficient mice
1832012019589608/02/12Igf-1 fusion polypeptides and therapeutic uses thereof
1842012018963507/26/12Methods for treating or preventing malaria by administering an antibody that specifically binds angiopoietin-2 (ang-2)
1852012019230007/26/12Common light chain mouse
1862012017868307/12/12Vegf antagonist formulations
1872012016468806/28/12High affinity human antibodies to human nerve growth factor
1882012013501005/31/12High affinity human antibodies to human il-4 receptor
1892012012867905/24/12Human antibodies to the glucagon receptor
1902012011464505/10/12Use of il-1 antagonists to treat pseudogout
1912012011465405/10/12Human antibodies to human tnf-like ligand 1a (tl1a)
1922012011466505/10/12Human antibodies to human rankl
1932012009756504/26/12Stabilized formulations containing anti-interleukin-4 receptor (il-4r) antibodies
1942012010014504/26/12Methods for treating b-cell lymphoma by administering an anti-cd20 antibody
1952012010103504/26/12Vegf antagonist formulations
1962012009382404/19/12Methods for treating pruritus by administering an antibody that specifically binds human par2
1972012009657204/19/12Mice that make vl binding proteins
1982012008792904/12/12Vegf antagonist formulations for intravitreal administration
1992012008300004/05/12Neuropeptide release assay for sodium channels
2002012007679003/29/12Anti-cd48 antibodies and uses thereof
2012012007086103/22/12Human lambda light chain mice
2022012007300403/22/12Hybrid light chain mice
2032012006462103/15/12Cell culture compositions capable of producing a vegf-binding fusion polypeptide
2042012005207203/01/12High affinity human antibodies to human il-4 receptor
2052012004544002/23/12Method of treating rheumatoid arthritis with an anti-il-6r antibody
2062012002140901/26/12Common light chain mouse
2072012001496801/19/12Stabilized formulations containing anti-ngf antibodies
2082012000369701/05/12High affinity antibodies to human il-6 receptor
2092011031834212/29/11Methods of using il-1 antagonists to treat autoinflammatory disease
2102011031153712/22/11Methods of using il-1 antagonists to treat familial mediterranean fever (fmf)
2112011030796612/15/11Mice expressing human voltage-gated sodium channels
2122011030796812/15/11Production of fertile xy animals from xy es cells
2132011029363012/01/11Antibodies to human gdf8
2142011028337611/17/11Methods of modifying eukaryotic cells
2152011026918711/03/11High affinity human antibodies to human il-18 receptor
2162011025614810/20/11Methods for treating hypercholesterolemia using antibodies to pcsk9
2172011025655610/20/11Humanized fcgr mice
2182011025658710/20/11High affinity human antibodies to human nerve growth factor
2192011025760110/20/11Vegf antagonist formulations for intravitreal administration
2202011025871010/20/11Methods of modifying eukaryotic cells
2212011019545408/11/11Common light chain mouse
2222011018917608/04/11Methods of treating diseases with dll4 antagonists
2232011018920008/04/11Methods of treating autoimmune diseases with dll4 antagonists
2242011017124107/14/11Stabilized formulations containing anti-interleukin-6 (il-6) antibodies
2252011016565007/07/11Fusion polypeptides capable of activating receptors
2262011015901506/30/11Human antibodies to human angiopoietin-like protein 4
2272011015090506/23/11Human antibodies to human delta like ligand 4
2282011015451206/23/11Humanized fc gamma r mice
2292011014593706/16/11Mice that make heavy chain antibodies
2302011010479905/05/11Multifunctional alleles
2312011008168104/07/11Human antibodies to human cd20 and method of using thereof
2322011006590203/17/11High affinity human antibodies to pcsk9
2332011005909503/10/11High affinity human antibodies to human protease-activated receptor-2
2342011004119602/17/11Mirna-regulated differentiation-dependent self-deleting cassette
2352011004119702/17/11Promoter-regulated differentiation-dependent self-deleting cassette
2362011002728602/03/11High affinity human antibodies to human angiopoietin-2
2372011002034201/27/11Igf-1 fusion polypeptides and therapeutic uses thereof
2382011001420801/20/11Method of treating osteoarthritis with an antibody to ngf
2392011000837401/13/11Use of il-1 antagonists to treat gout
2402010033010612/30/10Method of treating cancer with dll4 antagonist and chemotherapeutic agent
2412010033152712/30/10Readily isolated bispecific antibodies with native immunoglobulin format
2422010031662712/16/10Human antibodies to human il-6 receptor
2432010031663612/16/10Method of treating rheumatoid arthritis with an il-6r antibody
2442010030443612/02/10Fucosylation-deficient cells
2452010029110711/18/10High affinity human antibodies to human il-4 receptor
2462010029162611/18/10Enhanced expression and stability regions
2472010027993311/04/10Vegf antagonist formulations
2482010023380309/16/10Fusion polypeptides capable of activating receptors
2492010022178209/02/10Modified chimeric polypeptides with improved pharmacokinetic properties


ARCHIVE: New 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Regeneron Pharmaceuticals, Inc. in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Regeneron Pharmaceuticals, Inc. with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###

     SHARE
  
         


FreshNews promo